These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26704615)

  • 21. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas.
    Andrade DV; Warnes C; Young E; Katzelnick LC; Balmaseda A; de Silva AM; Baric RS; Harris E
    Sci Rep; 2019 Nov; 9(1):16258. PubMed ID: 31700029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.
    Montoya M; Gresh L; Mercado JC; Williams KL; Vargas MJ; Gutierrez G; Kuan G; Gordon A; Balmaseda A; Harris E
    PLoS Negl Trop Dis; 2013; 7(8):e2357. PubMed ID: 23951377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections.
    Libraty DH; Zhang L; Obcena A; Brion JD; Capeding RZ
    Acta Trop; 2015 Feb; 142():103-7. PubMed ID: 25460346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru.
    Forshey BM; Reiner RC; Olkowski S; Morrison AC; Espinoza A; Long KC; Vilcarromero S; Casanova W; Wearing HJ; Halsey ES; Kochel TJ; Scott TW; Stoddard ST
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004398. PubMed ID: 26848841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII.
    Chen J; Wen K; Li XQ; Yi HS; Ding XX; Huang YF; Pan YX; Hu DM; Di B; Che XY; Fu N
    Mol Med Rep; 2016 Aug; 14(2):1799-808. PubMed ID: 27357403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans.
    Moi ML; Takasaki T; Omatsu T; Nakamura S; Katakai Y; Ami Y; Suzaki Y; Saijo M; Akari H; Kurane I
    J Gen Virol; 2014 Mar; 95(Pt 3):591-600. PubMed ID: 24323638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.
    van Panhuis WG; Gibbons RV; Endy TP; Rothman AL; Srikiatkhachorn A; Nisalak A; Burke DS; Cummings DA
    J Infect Dis; 2010 Oct; 202(7):1002-10. PubMed ID: 20738205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.
    Moi ML; Ami Y; Shirai K; Lim CK; Suzaki Y; Saito Y; Kitaura K; Saijo M; Suzuki R; Kurane I; Takasaki T
    Am J Trop Med Hyg; 2015 Feb; 92(2):370-6. PubMed ID: 25548383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000.
    Chang SF; Huang JH; Chen LK; Su CL; Liao TL; Chien LJ; Lin TH; Su CJ; Shu PY
    J Microbiol Immunol Infect; 2008 Oct; 41(5):377-85. PubMed ID: 19122918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dengue virus infections in a cohort of schoolchildren from Maracay, Venezuela: a 2-year prospective study.
    Comach G; Blair PJ; Sierra G; Guzman D; Soler M; de Quintana MC; Bracho-Labadie M; Camacho D; Russell KL; Olson JG; Kochel TJ
    Vector Borne Zoonotic Dis; 2009 Feb; 9(1):87-92. PubMed ID: 18788903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance.
    Ng KH; Zhang SL; Tan HC; Kwek SS; Sessions OM; Chan CY; Liu ID; Lee CK; Tambyah PA; Ooi EE; Yap HK
    Cell Host Microbe; 2019 Nov; 26(5):601-605.e3. PubMed ID: 31676304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue virus infection-enhancing antibody activities against Indonesian strains in inhabitants of central Thailand.
    Yamanaka A; Oddgun D; Chantawat N; Okabayashi T; Ramasoota P; Churrotin S; Kotaki T; Kameoka M; Soegijanto S; Konishi E
    Microbes Infect; 2016 Apr; 18(4):277-84. PubMed ID: 26645957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.